


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

ELIGIBILITY

CONCURRENT COMPONENTS OF VISIT

DISPOSITION



DRE = digital rectal exam

NED = no evidence of disease

PSA = prostate specific antigen

¹ PSA < 0.1 ng/mL for status post prostatectomy and < 1 ng/mL for status post radiation therapy

² Category 1: status-post radical prostatectomy or radiation therapy; pathologic stage pT2, N0, M0, negative margins, or clinical stage cT2, N0, M0; Gleason score ≤ 7 and PSA < 0.1 ng/mL or < 1 ng/mL if treated with radiation therapy

³ Category 2: status-post prostatectomy or status-post prostatectomy plus radiation therapy; pathologic stage pT2, N0, M0, positive margins; Gleason score ≤ 7 and PSA < 0.1 ng/mL

⁴ As clinically indicated for patients with reported symptoms, failed to recover, borderline values or per provider's discretion. Can discontinue after 2 consecutive normal levels.

⁵ As clinically indicated if PSA is undetectable

⁶ Category 3: status-post prostatectomy or status-post prostatectomy plus radiation therapy or status-post radiation therapy; pathologic staging pT3, N0, M0; clinical stage, cT3, N0, M0; Gleason score 8-10 and PSA < 0.1 ng/mL or < 1 ng/mL if treated with radiation therapy only


⁷ GCC should be initiated by the **Primary Oncologist**. If Primary Oncologist is unavailable, Primary Team/Attending Physician to initiate GCC discussion and notify Primary Oncologist. Patients, or if clinically indicated, the Patient Representative should be informed of therapeutic and/or palliative options. GCC discussion should be consistent, timely, and re-evaluated as clinically indicated. The Advance Care Planning (ACP) note should be used to document GCC discussion. Refer to [GCC home page](#) (for internal use only).

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care.

ELIGIBILITY

CONCURRENT COMPONENTS OF VISIT

DISPOSITION



¹ PSA < 0.1 ng/mL for status post prostatectomy and < 1 ng/mL for status post radiation therapy

² See [Physical Activity, Nutrition, and Tobacco Cessation Treatment](#) algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

³ Includes [colorectal, liver, lung, pancreatic, and skin cancer screening](#)

⁴ Based on [Centers for Disease Control and Prevention \(CDC\) guidelines](#)

⁵ Consider use of Vanderbilt’s [ABCDE’s approach to cardiovascular health](#)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

SUGGESTED READINGS

- Ammenheuser, M. (2017, February 21). *The ABCDEs of caring for the heart during cancer treatment - and beyond*. Vanderbilt Health. <https://my.vanderbilthealth.com/heart-damage-chemotherapy-radiation/>
- Aus, G., Abbou, C. C., Bolla, M., Heidenreich, A., Schmid, H. P., Van Poppel, H., ... Zattoni, F. (2005). EAU guidelines on prostate cancer. *European Urology*, 48(4), 546-551. doi:10.1016/j.eururo.2005.06.001
- Buschemeyer, W. C., & Freedland, S. J. (2007). Obesity and prostate cancer: Epidemiology and clinical implications. *European Urology*, 52(2), 331-343. doi:10.1016/j.eururo.2007.04.069
- Centers for Disease Control and Prevention. (2024). *Recommendations for Ages 19 Years or Older, United States, 2024*. Retrieved from <https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>
- Graham, J., Baker, M., Macbeth, F., & Titshall, V. (2008). Diagnosis and treatment of prostate cancer: Summary of NICE guidance. *British Medical Journal*, 336(7644), 610-612. doi:10.1136/bmj.39498.525706.AD
- Hamdy, F. C., Donovan, J. L., Lane, J. A., Malcolm, M., Metcalfe, C., Holding, P., ... Robinson, M. (2016). 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. *New England Journal of Medicine*, 375, 1415-1424. doi:10.1056/MEJMoa1606220
- Kushi, L. H., Byers, T., Doyle, C., Bandera, E. V., McCullough, M., Gansler, T., ... Thun, M. J. (2006). American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. *CA: A Cancer Journal for Clinicians*, 56(5), 254-281. doi:10.3322/canjclin.56.5.254
- Ma, R. L., & Chapman, K. (2009). A systematic review of the effect of diet in prostate cancer prevention and treatment. *Journal of Human Nutrition and Dietetics*, 22(3), 187-199. doi:10.1111/j.1365-277X.2009.00946.x
- MD Anderson Institutional Policy #CLN1202 - Advance Care Planning Policy. Advance Care Planning (ACP) Conversation Workflow (ATT1925)
- National Comprehensive Cancer Network. (2023). *Prostate Cancer* (NCCN Guideline Version 4.2023). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
- National Comprehensive Cancer Network. (2024). *Prostate Cancer Early Detection*. (NCCN Guideline Version 1.2024). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf
- Obek, C., Neulander, E., Sadek, S., & Soloway, M. S. (1999). Is there a role for digital rectal examination in the followup of patients after radical prostatectomy? *The Journal of Urology*, 162(3), 762-764. doi:10.1097/00005392-199909010-00037
- Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., & Walsh, P. C. (1999). Natural history of progression after PSA elevation following radical prostatectomy. *JAMA*, 281(17), 1591-1597. doi:10.1001/jama.281.17.1591

Continued on next page

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

SUGGESTED READINGS - continued

- Thompson, I., Thrasher, J. B., Aus, G., Burnett, A. L., Canby-Hagino, E. D., Cookson, M. S., ... Goldenberg, S. L. (2007). Guideline for the management of clinically localized prostate cancer: 2007 update. *The Journal of Urology*, 177(6), 2106-2131. doi:10.1016/j.juro.2007.03.003
- Vassilikos, E. J., Yu, H., Trachtenberg, J., Nam, R. K., Narod, S. A., Bromberg, I. L., & Diamandis, E. P. (2000). Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. *Clinical Biochemistry*, 33(2), 115-123. doi:10.1016/S0009-9120(99)00099-5
- Ward, J. F., Blute, M. L., Slezak, J., Bergstralh, E. J., & Zincke, H. (2003). The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. *The Journal of Urology*, 170(5), 1872-1876. doi:10.1097/01.ju.0000091876.13656.2e

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.*

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Genitourinary Survivorship workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Curtis Pettaway, MD (Urology)

Workgroup Members

John W. Davis, MD (Urology)

Olga N. Fleckenstein, BS♦

Katherine Gilmore, BA, MPH (Cancer Survivorship)

Rincy Joby, MSN FNP-C, AGACNP BC (Genitourinary Medical Oncology)

Deborah A. Kuban, MD (Radiation Oncology)

Christopher J. Logothetis, MD (Genitourinary Medical Oncology)

Johnny L. Rollins, MSN, APRN, ANP-C (Survivorship)

Hannah Warr, MSN, RN, CPHON♦

♦ Clinical Effectiveness Development Team